TCDA stock forecast
Our latest prediction for Tricida Inc's stock price was made on the Sept. 30, 2022 when the stock price was at 10.48$.
In the short term (2weeks), TCDA's stock price should underperform the market by -2.94%. During that period the price should oscillate between -13.51% and +6.66%.
In the medium term (3months), TCDA's stock price should outperform the market by 8.16%. During that period the price should oscillate between -30.94% and +35.13%.Get email alerts
Create a solid portfolio with TCDA
About Tricida Inc
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. There are no FDA-approved treatments for chronic metabolic acidosis, a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.71$ per share.
The book value per share is 5.20$
Three months stock forecastSept. 30, 2022
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|